Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + Imatinib in CML
NCT00093639Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2004
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoints: Safety, tolerability, and biological activity at 6 months and Clinical efficacy in terms of 3-month improvement by at least one cytogenetic category. Started Aug 2004; status: completed.
02
Drugs
everolimus
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00093639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093639.